panitumumab

Ask MedXY AI

Latest news

Tag

AIdeep learningmCRC

Muscle-Bone Ratio: A New AI-Driven Biomarker for Anti-EGFR Response in Metastatic Colorectal Cancer

By MedXY|Jan 8, 2026

A deep learning-derived sarcopenia marker, the muscle-bone ratio (MBR), has been shown to predict the efficacy of anti-EGFR maintenance therapy in patients with RAS wild-type metastatic colorectal cancer, potentially identifying those who t

$Enhancing Quality of Life in KRASG12C-Mutated Chemorefractory Metastatic Colorectal Cancer: Insights from the CodeBreaK 300 Phase 3 Trial$

newsKRASG12Cmetastatic colorectal cancer

Enhancing Quality of Life in KRASG12C-Mutated Chemorefractory Metastatic Colorectal Cancer: Insights from the CodeBreaK 300 Phase 3 Trial

By MedXY|Oct 9, 2025

The phase 3 CodeBreaK 300 trial shows sotorasib plus panitumumab improves health-related quality of life and clinical outcomes in KRASG12C-mutated metastatic colorectal cancer compared to standard care.